Although epidermal growth factor receptor (EGFR) inhibitors have been employed to treat colorectal cancer (CRC) for decades with great success in patients with EGFR mutations, acquired-resistance inevitably occurs after long-term exposure, especially in those patients harboring mutations in KRAS gene. This evidence concerns the gene EGFR and colorectal carcinoma.